Treatment Information

Back

Kidney (Renal) Cancer treatment details. Biologic therapy.

University of Oxford, Oxford, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:2City/State/Province:Oxford
Treatments:Biologic therapyHospital:University of Oxford
Drugs:Journal:Link
Date:Nov 2004

Description:

Patients: This Phase II trial involved 25 patients with metastatic renal cell carcinoma, 17 men and 8 women. The median age was 62. Fifteen had undergone prior nephrectomy.

Treatment: The treatment consisted of a new antiangiogenic agent called IM862 (a naturally occurring dipeptide).

Toxicity: Toxicities “probably related” to the drug included grade 1-2 sinusitis and grade 1 headache. (There were several grade 3 toxicities such as fatigue, pain, and nausea/vomiting, but the authors concluded that “none were related to the study drug.”)

Results: There were no objective responses and the median overall survival was 7.9 months.

Support: One of the authors, G Deplanque was supported by a research grant from Aventis Oncology.

Correspondence: Dr. A.L. Harris




Back